"Lilly co-developed bamlanivimab with Canadian company AbCellera Biologics Inc. It was derived from a blood sample taken from one of the first U.S. patients to recover from Covid-19. Lilly licensed the second antibody, etesevimab, from Junshi Biosciences of China.
A 1,035-person study found that the two-drug cocktail reduced the combined risk of death and hospitalization by 70% compared with patients who received a placebo. Some 7% of patients in the study who received the placebo died or were hospitalized for Covid-19, versus 2% of those who received the Lilly combination. Some patients had side effects including certain allergic reactions.
Lilly and its manufacturing partner Amgen Inc. plan to make up to one million doses of etesevimab by mid-2021. About 100,000 doses are ready immediately and an additional 150,000 are expected to be available throughout the first quarter, Lilly said." [1]
1. U.S. News: Antibody Drug Cocktail Allowed
Loftus, Peter. Wall Street Journal, Eastern edition; New York, N.Y. [New York, N.Y]11 Feb 2021: A.8
Komentarų nėra:
Rašyti komentarą